Effects of recombinant human growth hormone on donor-site healing in severely burned children

David Herndon, Robert E. Barrow, Kelly R. Kunkel, Lyle Broemeling, Randi L. Rutan

Research output: Contribution to journalArticle

321 Citations (Scopus)

Abstract

The beneficial effects of growth hormone on wound healing in severely burned children were studied. Forty patients who were 2 to 18 years old, with 40% or more total body surface area (TBSA) and 20% or more TBSA full-thickness flame or scald burns, were randomized in a double-blind study to receive placebo or 0.1 mg/kg/day recombinant human growth hormone (rHGH) until the first donor site healed or to receive 0.2 mg/kg/day rHGH or placebo from admission throughout hospitalization. Patients receiving 0.2 mg/kg/day rHGH demonstrated significantly higher serum IGF-1 levels at 4.8 ± 1.7 U/mL compared to placebos at 1.6 ± 0.4 U/mL (p < 0.05) and a significant decrease in donor-site healing times compared to placebo (p < 0.05). Length of hospital stay (LOS/%TBSA) was decreased from 0.80 ± 0.10 days/%TBSA burned in the placebo group to 0.54 ± 0.04 days/%TBSA burned in the 0.2 mg/kg/day treatment group (p < 0.05). This translates, for the average 60% TBSA burned patient, to a decrease in LOS from 46 to 32 days.

Original languageEnglish (US)
Pages (from-to)424-429
Number of pages6
JournalAnnals of Surgery
Volume212
Issue number4
StatePublished - Oct 1990

Fingerprint

Human Growth Hormone
Body Surface Area
Growth Hormone
Tissue Donors
Placebos
Length of Stay
Insulin-Like Growth Factor I
Burns
Double-Blind Method
Wound Healing
Hospitalization
Serum

ASJC Scopus subject areas

  • Surgery

Cite this

Herndon, D., Barrow, R. E., Kunkel, K. R., Broemeling, L., & Rutan, R. L. (1990). Effects of recombinant human growth hormone on donor-site healing in severely burned children. Annals of Surgery, 212(4), 424-429.

Effects of recombinant human growth hormone on donor-site healing in severely burned children. / Herndon, David; Barrow, Robert E.; Kunkel, Kelly R.; Broemeling, Lyle; Rutan, Randi L.

In: Annals of Surgery, Vol. 212, No. 4, 10.1990, p. 424-429.

Research output: Contribution to journalArticle

Herndon, D, Barrow, RE, Kunkel, KR, Broemeling, L & Rutan, RL 1990, 'Effects of recombinant human growth hormone on donor-site healing in severely burned children', Annals of Surgery, vol. 212, no. 4, pp. 424-429.
Herndon D, Barrow RE, Kunkel KR, Broemeling L, Rutan RL. Effects of recombinant human growth hormone on donor-site healing in severely burned children. Annals of Surgery. 1990 Oct;212(4):424-429.
Herndon, David ; Barrow, Robert E. ; Kunkel, Kelly R. ; Broemeling, Lyle ; Rutan, Randi L. / Effects of recombinant human growth hormone on donor-site healing in severely burned children. In: Annals of Surgery. 1990 ; Vol. 212, No. 4. pp. 424-429.
@article{5f016f75f1de4250883d200a5b043f66,
title = "Effects of recombinant human growth hormone on donor-site healing in severely burned children",
abstract = "The beneficial effects of growth hormone on wound healing in severely burned children were studied. Forty patients who were 2 to 18 years old, with 40{\%} or more total body surface area (TBSA) and 20{\%} or more TBSA full-thickness flame or scald burns, were randomized in a double-blind study to receive placebo or 0.1 mg/kg/day recombinant human growth hormone (rHGH) until the first donor site healed or to receive 0.2 mg/kg/day rHGH or placebo from admission throughout hospitalization. Patients receiving 0.2 mg/kg/day rHGH demonstrated significantly higher serum IGF-1 levels at 4.8 ± 1.7 U/mL compared to placebos at 1.6 ± 0.4 U/mL (p < 0.05) and a significant decrease in donor-site healing times compared to placebo (p < 0.05). Length of hospital stay (LOS/{\%}TBSA) was decreased from 0.80 ± 0.10 days/{\%}TBSA burned in the placebo group to 0.54 ± 0.04 days/{\%}TBSA burned in the 0.2 mg/kg/day treatment group (p < 0.05). This translates, for the average 60{\%} TBSA burned patient, to a decrease in LOS from 46 to 32 days.",
author = "David Herndon and Barrow, {Robert E.} and Kunkel, {Kelly R.} and Lyle Broemeling and Rutan, {Randi L.}",
year = "1990",
month = "10",
language = "English (US)",
volume = "212",
pages = "424--429",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Effects of recombinant human growth hormone on donor-site healing in severely burned children

AU - Herndon, David

AU - Barrow, Robert E.

AU - Kunkel, Kelly R.

AU - Broemeling, Lyle

AU - Rutan, Randi L.

PY - 1990/10

Y1 - 1990/10

N2 - The beneficial effects of growth hormone on wound healing in severely burned children were studied. Forty patients who were 2 to 18 years old, with 40% or more total body surface area (TBSA) and 20% or more TBSA full-thickness flame or scald burns, were randomized in a double-blind study to receive placebo or 0.1 mg/kg/day recombinant human growth hormone (rHGH) until the first donor site healed or to receive 0.2 mg/kg/day rHGH or placebo from admission throughout hospitalization. Patients receiving 0.2 mg/kg/day rHGH demonstrated significantly higher serum IGF-1 levels at 4.8 ± 1.7 U/mL compared to placebos at 1.6 ± 0.4 U/mL (p < 0.05) and a significant decrease in donor-site healing times compared to placebo (p < 0.05). Length of hospital stay (LOS/%TBSA) was decreased from 0.80 ± 0.10 days/%TBSA burned in the placebo group to 0.54 ± 0.04 days/%TBSA burned in the 0.2 mg/kg/day treatment group (p < 0.05). This translates, for the average 60% TBSA burned patient, to a decrease in LOS from 46 to 32 days.

AB - The beneficial effects of growth hormone on wound healing in severely burned children were studied. Forty patients who were 2 to 18 years old, with 40% or more total body surface area (TBSA) and 20% or more TBSA full-thickness flame or scald burns, were randomized in a double-blind study to receive placebo or 0.1 mg/kg/day recombinant human growth hormone (rHGH) until the first donor site healed or to receive 0.2 mg/kg/day rHGH or placebo from admission throughout hospitalization. Patients receiving 0.2 mg/kg/day rHGH demonstrated significantly higher serum IGF-1 levels at 4.8 ± 1.7 U/mL compared to placebos at 1.6 ± 0.4 U/mL (p < 0.05) and a significant decrease in donor-site healing times compared to placebo (p < 0.05). Length of hospital stay (LOS/%TBSA) was decreased from 0.80 ± 0.10 days/%TBSA burned in the placebo group to 0.54 ± 0.04 days/%TBSA burned in the 0.2 mg/kg/day treatment group (p < 0.05). This translates, for the average 60% TBSA burned patient, to a decrease in LOS from 46 to 32 days.

UR - http://www.scopus.com/inward/record.url?scp=0025119217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025119217&partnerID=8YFLogxK

M3 - Article

VL - 212

SP - 424

EP - 429

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 4

ER -